The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia
The objective: to study the effect of immunomodulators on markers of the acute inflammation phase in patients with mild community-acquired pneumonia (CAP).Subjects and methods. Patients (n = 64) with mild CAP (39.62 ± 9.82 years, CRB – 650.15 ± 0.04 scores) were enrolled in the study. The patients w...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2021-05-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283922429050880 |
|---|---|
| author | M. P. Kostinov V. V. Gaynitdinova S. V. Kazharova V. N. Zorina V. B. Polischuk A. E. Vlasenko |
| author_facet | M. P. Kostinov V. V. Gaynitdinova S. V. Kazharova V. N. Zorina V. B. Polischuk A. E. Vlasenko |
| author_sort | M. P. Kostinov |
| collection | DOAJ |
| description | The objective: to study the effect of immunomodulators on markers of the acute inflammation phase in patients with mild community-acquired pneumonia (CAP).Subjects and methods. Patients (n = 64) with mild CAP (39.62 ± 9.82 years, CRB – 650.15 ± 0.04 scores) were enrolled in the study. The patients were divided into 2 groups: Group 1 (control) received only standard CAP therapy; in the other two groups, immunomodulators were prescribed simultaneously with standard therapy: in Group 2 – bacterial lysate (BL), in Group 3 – azoximer bromide (AB). In the patients, the blood levels of IL-6, TNF-α, C-reactive protein (CRP), lactoferrin were tested before treatment (day 1), and on days 13 and 60 of observation.Results. The initial levels of TNF-α, IL-6, CRP and lactoferrin in the patients were statistically significantly higher above normal ones. A significant decrease in the levels of TNF-α, IL-6, CRP was found in all patients on the 13th and 60th days of observation compared to the 1st day, the maximum reduction was observed in the patients receiving immunomodulators. The biggest decrease in the level of lactoferrin on the 60th day of observation was noted in the group of patients taking BL. The changes in the rate of TNF-α and IL-6 levels decrease on the 13th and 60th days were also statistically significantly more pronounced (compared to the control group). The changes in the rate of decreasing from the baseline on the 13th and 60th days in TNF-α in the BL Group made 44 [-64; -32]% and 85 [-89; -82]%; in the AB Group – 28 [-40; -20]% and 82 [-86; -80]%; in IL-6 in the BL group – 32 [-40; -18]% and 86 [-90; -85]%, in the AB group – 45 [-53; -38]% and 86 [-88; -84]%. In the control group, this parameter for TNF-α was 18 [-32; -8]% and 64 [-78; -56]%, for IL-6 – 11 [-20; -1]% and 75 [-81; -74]%.Conclusion. The addition of immunomodulators (BL, AB) to the therapy of patients with mild CAP results in statistically significant decrease in the blood levels of biomarkers of the acute inflammation phase on the 13th and 60th days. |
| format | Article |
| id | doaj-art-64fc36732b834ed998d7fd039e75767f |
| institution | OA Journals |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| publishDate | 2021-05-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj-art-64fc36732b834ed998d7fd039e75767f2025-08-20T01:47:41ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062021-05-01994364310.21292/2075-1230-2021-99-4-36-431526The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumoniaM. P. Kostinov0V. V. Gaynitdinova1S. V. Kazharova2V. N. Zorina3V. B. Polischuk4A. E. Vlasenko5Research Institute of Vaccines and Serums Named after I. I. Mechnikov; I. M. Sechenov First Moscow State Medical University (Sechenov University)I. M. Sechenov First Moscow State Medical University (Sechenov University)Research Institute of Vaccines and Serums Named after I. I. MechnikovInstitute of Toxicology of Federal Medical Biological AgencyResearch Institute of Vaccines and Serums Named after I. I. MechnikovNovokuznetsk State Institute for Doctors' Professional Development – Branch of Russian Medical Academy of Continuing Professional EducationThe objective: to study the effect of immunomodulators on markers of the acute inflammation phase in patients with mild community-acquired pneumonia (CAP).Subjects and methods. Patients (n = 64) with mild CAP (39.62 ± 9.82 years, CRB – 650.15 ± 0.04 scores) were enrolled in the study. The patients were divided into 2 groups: Group 1 (control) received only standard CAP therapy; in the other two groups, immunomodulators were prescribed simultaneously with standard therapy: in Group 2 – bacterial lysate (BL), in Group 3 – azoximer bromide (AB). In the patients, the blood levels of IL-6, TNF-α, C-reactive protein (CRP), lactoferrin were tested before treatment (day 1), and on days 13 and 60 of observation.Results. The initial levels of TNF-α, IL-6, CRP and lactoferrin in the patients were statistically significantly higher above normal ones. A significant decrease in the levels of TNF-α, IL-6, CRP was found in all patients on the 13th and 60th days of observation compared to the 1st day, the maximum reduction was observed in the patients receiving immunomodulators. The biggest decrease in the level of lactoferrin on the 60th day of observation was noted in the group of patients taking BL. The changes in the rate of TNF-α and IL-6 levels decrease on the 13th and 60th days were also statistically significantly more pronounced (compared to the control group). The changes in the rate of decreasing from the baseline on the 13th and 60th days in TNF-α in the BL Group made 44 [-64; -32]% and 85 [-89; -82]%; in the AB Group – 28 [-40; -20]% and 82 [-86; -80]%; in IL-6 in the BL group – 32 [-40; -18]% and 86 [-90; -85]%, in the AB group – 45 [-53; -38]% and 86 [-88; -84]%. In the control group, this parameter for TNF-α was 18 [-32; -8]% and 64 [-78; -56]%, for IL-6 – 11 [-20; -1]% and 75 [-81; -74]%.Conclusion. The addition of immunomodulators (BL, AB) to the therapy of patients with mild CAP results in statistically significant decrease in the blood levels of biomarkers of the acute inflammation phase on the 13th and 60th days.https://www.tibl-journal.com/jour/article/view/1529community-acquired pneumoniaimmunomodulatorsinflammatory mediatorscytokineslactoferrintreatment |
| spellingShingle | M. P. Kostinov V. V. Gaynitdinova S. V. Kazharova V. N. Zorina V. B. Polischuk A. E. Vlasenko The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia Туберкулез и болезни лёгких community-acquired pneumonia immunomodulators inflammatory mediators cytokines lactoferrin treatment |
| title | The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia |
| title_full | The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia |
| title_fullStr | The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia |
| title_full_unstemmed | The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia |
| title_short | The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia |
| title_sort | effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community acquired pneumonia |
| topic | community-acquired pneumonia immunomodulators inflammatory mediators cytokines lactoferrin treatment |
| url | https://www.tibl-journal.com/jour/article/view/1529 |
| work_keys_str_mv | AT mpkostinov theeffectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT vvgaynitdinova theeffectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT svkazharova theeffectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT vnzorina theeffectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT vbpolischuk theeffectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT aevlasenko theeffectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT mpkostinov effectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT vvgaynitdinova effectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT svkazharova effectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT vnzorina effectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT vbpolischuk effectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia AT aevlasenko effectofimmunomodulatorsonvariousmarkersoftheacuteinflammationphaseinpatientswithmildcommunityacquiredpneumonia |